Agreed. Waiting for deals on Asthma, CLI and Diabetic Ulcers as these are ready for partnering.
What's a partnering deal worth on each of these indications??
As per the companies last presentation:
"Valuable market opportunity: Estimated US$1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone"
Just for comparison below on market size.
GvHD
$USD 300m market size
$3m upfront (Fuji deal) alone
$60+m milestones
$30m p.a. royalties
CLI
$USD 1.4b market size (4.6x GvHD)
therefore approx
~$14m upfront
~$276+m milestones
~$138m p.a. royalties
Interesting times ahead
Ann: Positive 28-day Clinical Trial Data in Cohort B, page-77
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.99M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 29.5¢ | 27.0¢ | $3.372K | 11.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39000 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 1608 | 1 |
View Market Depth
| Last trade - 11.40am 01/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |